Company overview
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing RMD with another company.
| Daily close (USD) | $226.73 |
| Market capitalization (USD) | $32,706,325,339.38 |
| Price / earnings (TTM) | 21.47 |
| Price / book | 4.97 |
No matching rows. Clear the filter to see all records.
Read RMD's valuation metrics
Company size
ResMed Inc.'s recorded market capitalization is $32,706,325,339.38. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
RMD's recorded P/E is 21.47: about $21.47 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
RMD's recorded price-to-book ratio is 4.97. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research ResMed Inc. with Aurora
Use the snapshot above to ask a specific question about RMD. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow RMD's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.